Clinical trial
An Open-Label Study of Atomoxetine in Adolescents With…
NCT00191737 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191737 |
|---|---|
| Title | An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder |
| Official title | An Open-Label Study on Effectiveness and Tolerability of Atomoxetine, as Perceived by Patients, Parents, and Physicians in Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Atomoxetine |
| Enrollment | 147 |
| Start date | Oct 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: